Skip to main content
Clinical Trials/NCT05328375
NCT05328375
Completed
Not Applicable

Implementing Telehealth-enhanced Hybrid Cardiac Rehabilitation (THCR) Among Acute Coronary Syndrome Survivors: A Pilot Randomized Controlled Trial

Columbia University1 site in 1 country10 target enrollmentMarch 11, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Coronary Syndrome
Sponsor
Columbia University
Enrollment
10
Locations
1
Primary Endpoint
Number of Participants Who Are Successfully Enrolled Into the Pilot Study Per Month
Status
Completed
Last Updated
6 months ago

Overview

Brief Summary

This study investigates the feasibility of conducting a randomized controlled trial of telehealth-enhanced hybrid cardiac rehabilitation (THCR) compared with traditional cardiac rehabilitation (CR) among acute coronary syndrome (ACS) survivors. THCR is a novel, hybrid model that targets the same core components as traditional CR (e.g., exercise training, patient education, and risk factor management), but uses a mixture of telehealth, clinic-, and home-based activities to offer 24 CR sessions (5 clinic-based + 19 home-based) over 12 weeks.

Pilot study ran from March 2022 to May 2023. In 2023, intervention became unavailable, due to a telehealth vendor transition across the implementation site's healthcare system, which necessitated new remote patient monitoring platform to offer the experimental arm. Therefore, the study completed with 10 accrued.

Detailed Description

Cardiac Rehabilitation (CR) is a Class I, Level A secondary prevention program that significantly reduces reinfarction and mortality rates in acute coronary syndrome (ACS) survivors. Yet, fewer than 30% of eligible cardiac patients participate in and adhere to CR programs in the United States. One promising avenue for increasing CR participation and adherence is a telehealth-enhanced hybrid CR (THCR) model that combines telehealth, clinic- and home-based CR. Several expert groups have strongly endorsed hybrid CR models that integrate telehealth (i.e., mobile apps, remote monitoring devices) because of their ability to offer the "best of both worlds" (i.e., in-clinic supervision/safety and at-home convenience) while also promoting real-time patient-provider communication and reimbursement as a telemedicine service. Despite its potential, the feasibility of and degree to which THCR improves adherence (e.g., # of completed sessions) and clinical outcomes (e.g., functional capacity) relative to traditional CR requires additional investigation. To understand the feasibility of THCR, the investigator will conduct a single center, two-arm, 1:1 parallel group randomized pilot study comparing THCR with traditional CR among ACS patients (N=40) to evaluate the feasibility (e.g., recruitment, adherence) of conducting an adequately powered randomized controlled trial.

Registry
clinicaltrials.gov
Start Date
March 11, 2022
End Date
May 1, 2023
Last Updated
6 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Andrea Duran

Assistant Professor in the Department of Medicine

Columbia University

Eligibility Criteria

Inclusion Criteria

  • over the age of 18;
  • can speak and read English or Spanish;
  • confirmed ACS based on ICD-10 codes; and
  • had their index event within the past 12 months.

Exclusion Criteria

  • severe disabling chronic medical and/or psychiatric comorbidities determined on a case-by-case basis that prevent safe or adequate participation;
  • high-risk for adverse exercise-related cardiovascular events according to the AACVPR risk stratification criteria;
  • participated in \>1 CR program session;
  • deemed unable to comply with the protocol (either self-selected or indicated during screening that s/he could not complete all requested tasks). This includes, but is not limited to, patients with a level of cognitive impairment indicative of dementia, patients with current alcohol or substance abuse, patients with a significant movement or balance disorder that interferes with walking, patients with impaired circulation or poor perfusion that may impede pulse oximeter readings, and patients with severe mental illness (e.g., schizophrenia);
  • home-based environment deemed incompatible with the protocol and/or that prevent safe or adequate participation (either self-selected or indicated during screening/onboarding process); and
  • unavailable for follow-up for reasons such as terminal illness and imminent plans to leave the United States (as we have migrant or mobile patients due to their citizenship and work issues).

Outcomes

Primary Outcomes

Number of Participants Who Are Successfully Enrolled Into the Pilot Study Per Month

Time Frame: During enrollment, 11 months

As a measure of enrollment feasibility, the investigator will assess the number of participants who completed recruitment activities and were successfully consented and enrolled into the pilot study per month.

Mean Proportion of CR Sessions Completed by Participants Allocated to the THCR Intervention

Time Frame: Assessed after enrollment (baseline) and until pilot study completion (approximately 12 weeks)

As a measure of THCR adherence, the investigator will assess the proportion of CR sessions completed by participants allocated to the THCR intervention, which includes 19 home-based + 5 clinic-based sessions.

Secondary Outcomes

  • Proportion of Participants That Attend ≥1 CR Session After Randomization in Each Arm(During 12-week follow-up period (Up to 12 weeks))
  • Mean Proportion of CR Sessions Completed by Those Allocated to the Traditional CR Intervention(Assessed after enrollment (baseline) and until pilot study completion (approximately 12 weeks))
  • Proportion of Participants Who Report Adequate Feasibility of the THCR Intervention(At study completion (approximately 12 weeks))

Study Sites (1)

Loading locations...

Similar Trials